Efficacy and Safety of Propiverine Hydrochloride 40mg in Treatment of Overactive Bladder : Prospective, Multicenter, Observational study.
- Author:
Su Jin KIM
1
;
Won Yeal CHO
;
Jung Sik HUH
;
Ju Tae SEO
;
Sang Kuk YANG
;
Kyu Sung LEE
;
Ju Hwan LEE
;
Myung Soo CHOO
;
Ha Young KIM
;
Chul Hee PARK
;
Joon Chul KIM
Author Information
1. Department of Urology, The catholic University of Korea College of Medicine, Korea. kjc@catholic.ac.kr
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Overactive bladder;
Propiverine hydrochloride;
Treatment outcome
- MeSH:
Cholinergic Antagonists;
Humans;
Mouth;
Observational Study*;
Physical Examination;
Prospective Studies*;
Treatment Outcome;
Urinary Bladder, Overactive*
- From:Journal of the Korean Continence Society
2008;12(2):114-120
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: This study aims to compare the efficacy and safety of propiverine hydrochloride (propiverine) 40mg for the treatment of overactive bladder (OAB). MATERIAL AND METHODS: Total of 284 patients (male:86, female:198) with OAB were included in this study. The patients were treated with propiverine 20mg twice daily or 40mg once daily for 8 weeks. The initial evaluation included with history taking, physical examination, International Prostatic Symptom Score (IPSS), IPSS QoL and consecutive voiding diaries for 3 days. After a 8-week treatment, IPSS, IPSS QoL, patients perception of treatment benefit, global assessment of efficacy by physicain and safety were evaluated. RESULTS: Two hundred eighteen patients were treated with propiverine 20mg twice daily and 66 patients treated with 40mg once daily. The 59 patients had been treated previously with anticholinergics. After a 8-week treatment, IPSS score (total, voiding and storage subscore) and IPSS QoL were improved in all patients (p<0.05). After a 8-week with propiverine 40mg once daily, improvement of IPSS score was noted in the patients non-responsive to anticholinergics previously (p<0.05). The patients treated with propiverine 40mg once daily showed much more symptomatic improvements assessed by physicians than 20mg twice daily (p<0.05). The overall side effect was noted in the 13.4% patients and the most common side effect was dry mouth. CONCLUSION: Propiverine 40mg once daily is considered to reduce the symptom of OAB effectively and can be used safely in the patients with OAB. Treatment with propiverine 40mg is seemed to show more improvement in the unsatisfactory patients with previous anticholinergics.
